Skip to main content
SpringerLink
Log in

Hyponatremia in Cirrhosis

  • Chapter
  • First Online:
Complications of Cirrhosis

Abstract

Hyponatremia is a relatively common complication of cirrhosis in which there is kidney impairment in the capacity to eliminate solute-free water. This causes disproportionate water retention in relation to the retention of sodium, thus causing a reduction in serum sodium concentration and hypoosmolality. The main pathogenic factor responsible for hyponatremia is a nonosmotic hypersecretion of arginine vasopressin (AVP or antidiuretic hormone) from the neurohypophysis related to circulatory dysfunction. Hyponatremia in cirrhosis is associated with increased morbidity and mortality. The current standard of care based on fluid restriction to 1.5 L/day is rarely effective. Other approaches such as albumin infusion and the use of vaptans, which act by antagonizing specifically the effects of AVP on the V2 receptors located in the kidney tubules, have been evaluated for their role in the management of hyponatremia. Short-term treatment with vaptans is associated with a marked increase in renal solute-free water excretion and improvement of hyponatremia; however, their use in patients with end-stage liver disease is limited by hepatoxic effects of some of these drugs. This chapter discusses the evaluation and management of patients with cirrhosis and ascites.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ginès P, Cárdenas A, Schrier R. Liver disease and the kidney. In: Schrier R, editor. Diseases of the kidney and urinary tract. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. pp. 2179–205.

    Google Scholar 

  2. Adrogue HJ, Madias NE. Hyponatremia. N Engl J Med. 2000;342:1581–9.

    Article  CAS  PubMed  Google Scholar 

  3. Ginès P, Berl T, Bernardi M, et al. Hyponatremia in cirrhosis: from pathogenesis to treatment. Hepatology. 1998;28:851–64.

    Article  PubMed  Google Scholar 

  4. Gianotti R, Cárdenas A. Hyponatremia in cirrhosis. Gastroenterol Rep (Oxf). 2014;2(1):21–6.

    Article  Google Scholar 

  5. Ginès P, Angeli P, Lenz K, Möller S, Moore K, Moreau R, Larsen M, Bernardi M. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53:397–417.

    Article  Google Scholar 

  6. Planas R, Montoliu S, Ballesté B, et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol. 2006;4:1385–94.

    Article  PubMed  Google Scholar 

  7. Angeli P, Wong F, Watson H, Gines P. Hyponatremia in cirrhosis: results of a patient population survey. Hepatology. 2006;44:1535–42.

    Article  CAS  PubMed  Google Scholar 

  8. Biggins S, Rodriguez HJ, Bachetti P, et al. Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology. 2005;41:32–9.

    Article  CAS  PubMed  Google Scholar 

  9. Londoño MC, Cardenas A, Guevara M, et al. MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. Gut. 2007;56:1283–90.

    Article  PubMed Central  PubMed  Google Scholar 

  10. Londoño MC, Guevara M, Rimola A, et al. Hyponatremia impairs early posttransplantation outcome in patients with cirrhosis undergoing liver transplantation. Gastroenterology. 2006;130:1135–43.

    Article  PubMed  Google Scholar 

  11. Dawwas MF, Lewsey JD, Neuberger J, et al. The impact of serum sodium concentration on mortality after liver transplantation: a cohort multicenter study. Liver Transplant. 2007;13:1115–24.

    Article  Google Scholar 

  12. Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, Benson JT, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med. 2008;359:1018–26.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Biggins SW, Kim WR, Terrault NA, Saab S, Balan V, Schiano T, et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology. 2006;130:1652–60.

    Article  PubMed  Google Scholar 

  14. Ruf AE, Kremers WK, Chavez LL, Descalzi VI, Podesta LG, Villamil FG. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transplant. 2005;11:336–43.

    Article  Google Scholar 

  15. Pereira G, Guevara M, Fagundes C, Solá E, Rodríguez E, Fernández J, et al. Renal failure and hyponatremia in patients with cirrhosis and skin and soft tissue infection. A retrospective study. J Hepatol. 2012;56:1040–6.

    Article  PubMed  Google Scholar 

  16. Ishikawa S, Schrier RW. Pathogenesis of hyponatremia: the role of arginine vasopressin. In: Ginès P, Arroyo V, Rodes J, Schrier R, editors. Ascites and renal dysfunction in liver disease. 2nd ed. Oxford: Blackwell; 2005. pp. 305–14.

    Google Scholar 

  17. Thibonnier M, Conarty DM, Preston JA, et al. Molecular pharmacology of human vasopressin receptors. Adv Exp Med Biol. 1998;449:251–76.

    Article  CAS  PubMed  Google Scholar 

  18. Kwon TH, Hager H, Nejsum LN, et al. Physiology and pathophysiology of renal aquaporins. Semin Nephrol. 2001;21:231–8.

    Article  CAS  PubMed  Google Scholar 

  19. Nielsen S, Frokiaer J, Marples D, et al. Aquaporins in the kidney: from molecules to medicine. Physiol Rev. 2002;82:205–44.

    CAS  PubMed  Google Scholar 

  20. Elhassan EA, Schrier RW. Hyponatremia: diagnosis, complications, and management including V2 receptor antagonists. Curr Opin Nephrol Hypertens. 2011;20:161–8.

    Article  CAS  PubMed  Google Scholar 

  21. Guevara M, Baccaro ME, Torre A, et al. Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis: a prospective study with time-dependent analysis. Am J Gastroenterol. 2009;104:1382–9.

    Article  PubMed  Google Scholar 

  22. Riggio O, Angeloni S, Salvatori FM, et al. Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts. Am J Gastroenterol. 2008;103:2738–46.

    Article  PubMed  Google Scholar 

  23. Guevara M, Baccarro ME, Rios J, et al. Risk factors for hepatic encephalopathy in patients with cirrhosis and refractory ascites: relevance of serum sodium concentration. Liver Int. 2010;30:1137–42.

    Article  CAS  PubMed  Google Scholar 

  24. Haussinger D, Schliess F. Pathogenetic mechanisms of hepatic encephalopathy. Gut. 2008;57:1156–65.

    Article  CAS  PubMed  Google Scholar 

  25. Córdoba J, García-Martinez R, Simón-Talero M. Hyponatremic and hepatic encephalopathies: similarities, differences and coexistence. Metab Brain Dis. 2010;25:73–80.

    Article  PubMed  Google Scholar 

  26. Follo A, Llovet JM, Navasa M, Planas R, Forns X, Francitorra A, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: course, predictive factors and prognosis. Hepatology. 1994;20:1495–501.

    Article  CAS  PubMed  Google Scholar 

  27. Ginès A, Escorsell A, Ginès P, Saló J, Jiménez W, Inglada L, et al. Incidence, predictive factors, and prognosis of hepatorenal syndrome in cirrhosis. Gastroenterology. 1993;105:229–36.

    PubMed  Google Scholar 

  28. Solà E, Guevara M, Rodriguez E, Barreto R, Pavesi M, Arroyo V, Smadja-Lew E, Watson H, Ginés P. Hyponatremia is a major factor of the impaired health-related quality of life in patients with cirrhosis and ascites. J Hepatol. 2012;56(Suppl 2):S256.

    Article  Google Scholar 

  29. Furst H, Hallows KR, Post J, Chen S, Kotzker W, Goldfarb S, Ziyadeh FN, Neilson EG. The urine/plasma electrolyte ratio: a predictive guide to water restriction. Am J Med Sci. 2000;319(4):240–4.

    Article  CAS  PubMed  Google Scholar 

  30. Jalan R, Mookerjee R, Cheshire L, Williams R, et al. Albumin infusion for severe hyponatremia in patients with refractory ascites: a randomized clinical trial. J Hepatol. 2007;46:232A.

    Article  Google Scholar 

  31. McCormick PA, Mistry P, Kaye G, Burroughs AK, McIntyre N. Intravenous albumin infusion is an effective therapy for hyponatraemia in cirrhotic patients with ascites. Gut. 1990;31:204–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  32. Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet. 2008;371:1624–32.

    Article  CAS  PubMed  Google Scholar 

  33. Wong F, Blei AT, Blendis LM, Thuluvath PJ. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology. 2003;37:182–91.

    Article  CAS  PubMed  Google Scholar 

  34. Gerbes AL, Gulberg V, Ginès P, Decaux G, Gross P, Gandjini H, Djian J, VPA Study Group. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology. 2003;124:933–9.

    Article  CAS  PubMed  Google Scholar 

  35. Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099–112.

    Article  CAS  PubMed  Google Scholar 

  36. Ginès P, Wong F, Watson H, et al. Effects of satavaptan, a selective vasopressin V2 receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology. 2008;48:204–13.

    Article  PubMed  Google Scholar 

  37. Cárdenas A, Ginès P, Marotta P, et al. The safety and efficacy of tolvaptan, an oral vasopressin antagonist in the treatment of hyponatremia in cirrhosis. J Hepatol. 2012;56:571–8.

    Article  PubMed  Google Scholar 

  38. O’Leary JG, Davis GL. Conivaptan increases serum sodium in hyponatremic patients with end-stage liver disease. Liver Transplant. 2009;15:1325–9.

    Article  Google Scholar 

  39. Dahl E, Gluud LL, Kimer N, Krag A. Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia. Aliment Pharmacol Ther. 2012;36(7):619–26.

    Article  CAS  PubMed  Google Scholar 

  40. Wong F, Watson H, Gerbes A, et al. Satavaptan for the management of ascites in cirrhosis. Efficacy and safety across the spectrum of ascites severity. Gut. 2012;61:108–1.

    Article  CAS  PubMed  Google Scholar 

  41. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS, TEMPO 3:4 Trial Investigators. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367(25):2407–18.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  42. Okita K, Sakaida I, Okada M, Kaneko A, Chayama K, Kato M, et al. A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosis. J Gastroenterol. 2010;45:979–87.

    Article  CAS  PubMed  Google Scholar 

  43. Samsca (Tolvaptan): Drug Safety Communication—FDA Limits duration and usage due to possible liver injury leading to organ transplant or death. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm350185.htm. Accessed 6 April 2013.

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, USA

    Elliot B. Tapper

  2. Institut de Malalties Digestives i Metaboliques, University of Barcelona, Hospital Clinic, Villarroel 170, Esc 3-2, 08036, Barcelona, Spain

    Andrés Cárdenas MD, MMSc, AGAF

Authors
  1. Elliot B. Tapper
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrés Cárdenas MD, MMSc, AGAF
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrés Cárdenas MD, MMSc, AGAF .

Editor information

Editors and Affiliations

  1. Department of Transplant, Mayo Clinic, Jacksonville, Florida, USA

    Andrew P. Keaveny

  2. Institut de Malalties Digestives i Metaboliques, University of Barcelona, Barcelona, Spain

    Andrés Cárdenas

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Tapper, E., Cárdenas, A. (2015). Hyponatremia in Cirrhosis. In: Keaveny, A., Cárdenas, A. (eds) Complications of Cirrhosis. Springer, Cham. https://doi.org/10.1007/978-3-319-13614-1_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-13614-1_14

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-13613-4

  • Online ISBN: 978-3-319-13614-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation